http://pharmabiz.com/NewsDetails.aspx?aid=153816&sid=2 Web13 apr. 2024 · The open-label Phase 2 JEWELFISH study (NCT03032172) enrolled 174 SMA patients, ages 6 months to 60 years, who previously received other SMA-targeting therapies. These include Genentech’s investigational compounds, Biogen’s Spinraza (nusinersen) — the first approved SMA-targeted therapy — and Novartis’ one-time gene …
New Roche data for Evrysdi show improved motor function in pre ...
Web11 jun. 2024 · Roche has reported new interim data from two studies of Evrysdi (risdiplam); JEWELFISH and RAINBOWFISH. Data from JEWELFISH, an ongoing open-label study primarily evaluating the safety of Evrysdi in people aged 1 to 60 years who have been previously treated with another SMA-targeting therapy, including nusinersen and … Web26 okt. 2024 · It was conducted in five study sites in South Africa, Uganda, Zambia and India. 1204 children aged under 16 years participated in the trial, including 127 children … insurance agent testimonials
Pooled safety data from the risdiplam (RG7916) clinical trial
Web24 jan. 2024 · A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy (Jewelfish) January 19, 2024 updated by: Hoffmann-La Roche An Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Risdiplam (RO7034067) in Adult and Pediatric … Webstudy to investigate the safety, tolerability, pharmacokinetics and PK/PD relationship of RO7034067 patients ... AVXS-101 or olesoxime (BP39054/JEWELFISH) Study 6 . Multi-centre, single-arm, open-label study to investigate the efficacy, safety and tolerability, and PK/PD of RO7034067 in infants genetically diagnosed with SMA and pre ... Web11 jun. 2024 · The study is currently recruiting. JEWELFISH (NCT03032172) is an open-label exploratory trial designed to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics ... jobs highline school district